Abnova and Japan National Cancer Center Research Institute Present Pancreatic Cancer Biomarker Findings at 8th JHUPO Conference

Neihu, Taiwan (April 2, 2010).

Abnova and Japan National Cancer Center Research Institute will be presenting the result of the pancreatic cancer biomarker findings at the upcoming 8th Japan Human Proteome Organization (JHUPO) conference on July 26-27, 2010 in Tokyo, Japan. This is the culmination of more than one and half years of research discovery and validation work utilizing antibody-based tissue microarray profiling to identify novel protein biomarkers which are preferentially expressed on cancer tissue followed by confirmation of the same proteins released into the blood stream. These biomarkers are benchmarked against the current standard biomarker, CA-19.9 for pancreatic cancer. The newly discovered biomarkers hold great value for early detection, diagnostic, prognostic, and theranostic applications in the management and treatment of pancreatic patients. Abnova has the exclusive right in the commercialization of the derived biomarkers and National Cancer Center Research Institute will receive royalty from sales of commercial products.

Human tissue and sera are the two main sources of clinical sample available to clinicians and researchers for investigation of biomarkers which have gained increased importance in new era of personalized medicine. The approach undertook by Abnova and Japan National Cancer Center for the discovery of pancreatic cancer biomarkers is unprecedented. Abnova is a biotech company specializing in high throughput monoclonal antibody production. Japan National Cancer Center is a distinguished center of excellence for research and treatment of cancer patients. Leveraging Abnova's large collection of monoclonal antibodies and National Cancer Center's well-maintained archive of human samples and clinical records, two parties joint force to apply more than one thousand monoclonal antibodies to pathological specimens and compared protein expression profiles of pancreatic cancer versus normal patients. Relevant protein biomarkers are then evaluated for their presence in sera by sandwich ELISA technique for quantitative analysis. Protein levels are also compared to the levels of normal individuals for evaluation and verification of statistical significance. For the most part, the antibody screening and tissue section staining can be automated. However, immunohistochemical interpretation and subsequent serum validation work have taken more time.

The study will demonstrate the utility and collective power of large-scale monoclonal antibody screening and protein expression profiling. The discovered biomarkers will challenge us on our understanding of pancreatic cancer and reinforce the complexity of biology and disease process. Such high throughput, antibody screening platform can be readily applied to all the major cancers for biomarker discovery and validation. It is an invaluable system for translational research and new diagnostic and therapeutic developments.

Abnova and Japan National Cancer Center Research Institute Present Pancreatic Cancer Biomarker Findings at 8th JHUPO Conference

By: Abnova

POST COMMENT

Sterling's Derma Mist for Psoriasis Treatment The Way In Which Breast Chemotherapy Can Be Used To Defeat Breast Cancer Tailor's Bunionette and its Treatment Your Thyroid And Iodine: Are Hypothyroidism Iodine Treatments Effective? Four Stages of Lung Cancer Malignant Fibrous Histiocytoma Treatment India Natural Anxiety Treatments You Should Know Pineal Parenchymal tumor, Pineal Parenchymal tumor Treatment in India Pleural Mesothelioma Surgery in India, Pleural Mesothelioma Surgery, Lung cancer surgery in India information about Vulvar Cancer Treatment in India The Facts About Option Treatments Holistic Well being Treatment Increasing in Reputation Throughout the world Best pay monthly deals - Maximum Satisfaction Delivered